Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Key Drivers
3.1.1. Growing Nash Affected Population
3.1.2. Surging Prevalence Of Obesity And Diabetes
3.1.3. Increasing Occurrence Of Chronic Diseases
3.1.4. Surging Awareness Of Non-Alcoholic Fatty Liver Disease
3.2. Key Restraints
3.2.1. Side-Effects And Risks Associated With Nash Therapeutics
3.2.2. Lack Of Specialized Diagnostic Test For Non-Alcoholic Fatty Liver Disease (Nafld)

4. Key Analytics
4.1. Porter’S Five Forces Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Impact Of Covid-19 On Non-Alcoholic Steatohepatitis (Nash) Biomarker Market
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insights

5. Market By Type
5.1. Serum Biomarker
5.2. Hepatic Fibrosis Biomarker
5.3. Apoptosis Biomarker
5.4. Oxidative Stress Biomarker
5.5. Other Types

6. Market By End-User
6.1. Pharma & Cro Industry
6.2. Diagnostic Lab
6.3. Academic Research Key
6.4. Hospital

7. Geographical Analysis
7.1. Asia Pacific
7.1.1. Market Size & Estimates
7.1.2. Key Growth Enablers
7.1.3. Key Challenges
7.1.4. Key Players
7.1.5. Country Analysis
7.1.5.1. China
7.1.5.2. Japan
7.1.5.3. Australia & New Zealand
7.1.5.4. India
7.1.5.5. South Korea
7.1.5.6. Thailand
7.1.5.7. Indonesia
7.1.5.8. Vietnam
7.1.5.9. Rest Of Asia Pacific

8. Competitive Landscape
8.1. Key Strategic Developments
8.1.1. Merger & Acquisitions
8.1.2. Product Launch & Developments
8.1.3. Partnership, Contract/Agreement & Collaboration
8.1.4. Business Expansion/ Approval/ Announcement
8.2. Company Profile
8.2.1. Allergan Plc (Acquired By Abbvie)
8.2.2. Astrazeneca
8.2.3. Bristol-Myers Squibb Company
8.2.4. Genfit Sa
8.2.5. Gilead Sciences Inc
8.2.6. Madrigal Pharmaceuticals
8.2.7. Merck & Co
8.2.8. Novartis Ag
8.2.9. Novo Nordisk
8.2.10. Pfizer Inc
8.2.11. Siemens Healthineers
8.2.12. Viking Therapeutics
8.2.13. Zydus Cadila



List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Type, In 2020
Figure 6: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Serum Biomarker, 2021-2028 (In $ Million)
Figure 7: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Hepatic Fibrosis Biomarker, 2021-2028 (In $ Million)
Figure 8: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Apoptosis Biomarker, 2021-2028 (In $ Million)
Figure 9: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Oxidative Stress Biomarker, 2021-2028 (In $ Million)
Figure 10: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Other Types, 2021-2028 (In $ Million)
Figure 11: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By End-User, In 2020
Figure 12: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Pharma & Cro Industry, 2021-2028 (In $ Million)
Figure 13: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Diagnostic Lab, 2021-2028 (In $ Million)
Figure 14: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Academic Research Key, 2021-2028 (In $ Million)
Figure 15: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, By Hospital, 2021-2028 (In $ Million)
Figure 16: Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, Country Outlook, 2020 & 2028 (In %)
Figure 17: China Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 18: Japan Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 19: Australia & New Zealand Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 20: India Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 21: South Korea Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 22: Thailand Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 23: Indonesia Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 24: Vietnam Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)
Figure 25: Rest Of Asia Pacific Non-Alcoholic Steatohepatitis (Nash) Biomarker Market, 2021-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER
TABLE 2: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: LEADING PLAYERS OPERATING IN ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET